Michael L. Washburn

708 total citations · 1 hit paper
13 papers, 546 citations indexed

About

Michael L. Washburn is a scholar working on Immunology, Epidemiology and Molecular Biology. According to data from OpenAlex, Michael L. Washburn has authored 13 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 7 papers in Epidemiology and 3 papers in Molecular Biology. Recurrent topics in Michael L. Washburn's work include Immune Response and Inflammation (6 papers), Influenza Virus Research Studies (3 papers) and Liver Disease Diagnosis and Treatment (3 papers). Michael L. Washburn is often cited by papers focused on Immune Response and Inflammation (6 papers), Influenza Virus Research Studies (3 papers) and Liver Disease Diagnosis and Treatment (3 papers). Michael L. Washburn collaborates with scholars based in United States, United Kingdom and China. Michael L. Washburn's co-authors include Kovalev Gi, Lishan Su, Liguo Zhang, Moses T. Bility, Alexander Ploß, Charles M. Rice, Adam Buntzman, J. A. Frelinger, Rui Wang and Qi Jiang and has published in prestigious journals such as Blood, The Journal of Immunology and Gastroenterology.

In The Last Decade

Michael L. Washburn

13 papers receiving 542 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease

2011 220 citations Michael L. Washburn, Moses T. Bility et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael L. Washburn United States	11	250	218	175	120	79	13	546
Carine Brinster France	11	447 1.8×	177 0.8×	169 1.0×	120 1.0×	38 0.5×	22	719
Guillemette Masse‐Ranson France	8	214 0.9×	92 0.4×	74 0.4×	59 0.5×	49 0.6×	8	375
Simon Hellier United Kingdom	8	232 0.9×	416 1.9×	498 2.8×	79 0.7×	51 0.6×	9	780
Paula J. Biesta Netherlands	16	506 2.0×	359 1.6×	246 1.4×	159 1.3×	30 0.4×	21	819
Natasha Corbitt United States	13	259 1.0×	180 0.8×	44 0.3×	199 1.7×	49 0.6×	15	593
Antony Chen United States	9	356 1.4×	357 1.6×	280 1.6×	53 0.4×	30 0.4×	14	661
Mats Alheim Sweden	12	147 0.6×	204 0.9×	200 1.1×	79 0.7×	28 0.4×	16	456
Jun Cheng China	13	394 1.6×	239 1.1×	196 1.1×	125 1.0×	34 0.4×	44	686
Lucy Golden-Mason United States	6	614 2.5×	159 0.7×	185 1.1×	84 0.7×	30 0.4×	6	756
Denise Teoh United Kingdom	8	282 1.1×	171 0.8×	95 0.5×	47 0.4×	38 0.5×	9	449

Countries citing papers authored by Michael L. Washburn

Since Specialization

Citations

This map shows the geographic impact of Michael L. Washburn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Washburn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Washburn more than expected).

Fields of papers citing papers by Michael L. Washburn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Washburn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Washburn. The network helps show where Michael L. Washburn may publish in the future.

Co-authorship network of co-authors of Michael L. Washburn

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Washburn. A scholar is included among the top collaborators of Michael L. Washburn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Washburn. Michael L. Washburn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Steeghs, Neeltje, Aaron R. Hansen, Glenn J. Hanna, et al.. (2022). Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development. Clinical and Translational Science. 15(11). 2625–2639. 12 indexed citations

Hug, Bruce A., et al.. (2020). Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study. Clinical Therapeutics. 42(8). 1519–1534.e33. 17 indexed citations

Scott, M.J., Amanda Jowett, Peter Ertl, et al.. (2020). Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies. mAbs. 12(1). 1755069–1755069. 8 indexed citations

Washburn, Michael L., Zhang Wang, Andrew H. Walton, et al.. (2019). T Cell– and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer. The Journal of Immunology. 203(7). 1897–1908. 38 indexed citations

Washburn, Michael L., et al.. (2019). Therapeutically Attenuating Neutrophil Recruitment With a CXCR2 Antagonist in Combination With Oseltamivir Ameliorates Influenza-Induced Lung Injury and Disease. Open Forum Infectious Diseases. 6(4). ofz106–ofz106. 12 indexed citations

Chen, Shuguang, et al.. (2019). Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza. Open Forum Infectious Diseases. 6(4). ofz072–ofz072. 15 indexed citations

Chen, Shuguang, Michael L. Washburn, Andrew J. Peat, et al.. (2019). Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza. Open Forum Infectious Diseases. 6(4). ofz163–ofz163. 26 indexed citations

Washburn, Michael L., et al.. (2013). Regulatory T Cells Prevent Liver Fibrosis During HIV Type 1 Infection in a Humanized Mouse Model. The Journal of Infectious Diseases. 209(7). 1039–1044. 20 indexed citations

Bility, Moses T., et al.. (2012). Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nature Protocols. 7(9). 1608–1617. 60 indexed citations

10.

Washburn, Michael L., Moses T. Bility, Liguo Zhang, et al.. (2011). A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease. Gastroenterology. 140(4). 1334–1344. 220 indexed citations breakdown →

11.

Washburn, Michael L., Kovalev Gi, Ekaterina P. Koroleva, Yang‐Xin Fu, & Lishan Su. (2010). LIGHT Induces Distinct Signals to Clear an AAV-Expressed Persistent Antigen in the Mouse Liver and to Induce Liver Inflammation. PLoS ONE. 5(5). e10585–e10585. 6 indexed citations

12.

Hewitt, F. Curtis, Chengwen Li, Steven J. Gray, et al.. (2009). Reducing the Risk of Adeno-Associated Virus (AAV) Vector Mobilization with AAV Type 5 Vectors. Journal of Virology. 83(8). 3919–3929. 24 indexed citations

13.

Jiang, Qi, Liguo Zhang, Rui Wang, et al.. (2008). FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2−/−γC−/− mice in vivo. Blood. 112(7). 2858–2868. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact